COGNITION THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.91 USD | -1.04% |
|
-4.50% | +3.24% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Cognition The...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.91
USD
Average target price
6.667
USD
Spread / Average Target
+249.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.24% | 76.47M | |
| -3.46% | 102B | |
| +1.41% | 96.09B | |
| +2.13% | 22.28B | |
| -15.84% | 21.4B | |
| -9.21% | 18.14B | |
| -39.98% | 17.02B | |
| -14.65% | 16.09B | |
| +4.39% | 13.83B | |
| +31.35% | 11.97B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Transcript : Cognition Therapeutics, Inc. - Special Call
